Xeris Biopharma Holdings Inc (NASDAQ:XERS) has a beta value of 1.80 and has seen 0.57 million shares traded in the recent trading session. The company, currently valued at $500.91M, closed the recent trade at $3.36 per share which meant it gained $0.18 on the day or 5.66% during that session. The XERS stock price is -8.33% off its 52-week high price of $3.64 and 49.7% above the 52-week low of $1.69. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.33 million shares traded. The 3-month trading volume is 1.58 million shares.

The consensus among analysts is that Xeris Biopharma Holdings Inc (XERS) is Buy stock at the moment, with a recommendation rating of 1.33. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.06.

Xeris Biopharma Holdings Inc (NASDAQ:XERS) trade information

Over the past 30 days, the shares of Xeris Biopharma Holdings Inc (NASDAQ:XERS) have changed 4.02%. Short interest in the company has seen 10.15 million shares shorted with days to cover at 5.67.

Wall Street analysts have a consensus price target for the stock at $5.75, which means that the shares’ value could jump 41.57% from the levels at last check today. The projected low price target is $3.0 while the price target rests at a high of $6.6. In that case, then, we find that the latest price level in today’s session is -96.43% off the targeted high while a plunge would see the stock lose 10.71% from the levels at last check today.

Xeris Biopharma Holdings Inc (XERS) estimates and forecasts

Figures show that Xeris Biopharma Holdings Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 51.35% over the past 6 months, with this year growth rate of 8.89%, compared to 17.00% for the industry. Revenue growth from the last financial year stood is estimated to be 21.83%.

6 analysts offering their estimates for the company have set an average revenue estimate of 56.74M for the current quarter. 3 have an estimated revenue figure of 53.67M for the next ending quarter. Year-ago sales stood 44.39M and 40.64M respectively for this quarter and the next, and analysts expect sales will grow by 27.82% for the current quarter and 21.83% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 38.13% over the past 5 years.

XERS Dividends

Xeris Biopharma Holdings Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Xeris Biopharma Holdings Inc (NASDAQ:XERS)’s Major holders

Insiders own 3.91% of the company shares, while shares held by institutions stand at 43.81% with a share float percentage of 45.59%. Investors are also buoyed by the number of investors in a company, with Xeris Biopharma Holdings Inc having a total of 186.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 10.33 million shares worth more than $23.25 million. As of 2024-06-30, BLACKROCK INC. held 7.3531% of shares outstanding.

The other major institutional holder is VANGUARD GROUP INC, with the holding of over 7.66 million shares as of 2024-06-30. The firm’s total holdings are worth over $17.23 million and represent 5.4492% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. As of Jun 30, 2024, the former fund manager holds about 2.85% shares in the company for having 4.25 shares of worth $14.59 million while later fund manager owns 3.74 shares of worth $12.81 million as of Aug 31, 2024, which makes it owner of about 2.51% of company’s outstanding stock.